News
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial outlook ...
Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...
Novo Nordisk A/S is replacing Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker wrestles with increased ...
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
1d
Adweek on MSNEli Lilly's Big Task: Become a Loved and Trusted Pharma BrandA new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...
Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...
17h
Zacks Investment Research on MSNEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on ItEli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
14hon MSN
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results